Follow @TMFMassimo
Recent articles
Patent Expirations AbbVie Investors Need to Watch
Max Macaluso and Dave Williamson | Sep 17, 2013
A look at AbbVie's most important patent expirations.
Key Problems Behind Teva's Lackluster 2013
Max Macaluso and Dave Williamson | Sep 15, 2013
Why are shares of Teva up only 2.7% since the start of 2013?
Market Checkup: 2 Turnaround Stories to Watch
Max Macaluso and Dave Williamson | Sep 10, 2013
The Motley Fool's health care show, Market Checkup, for Sept. 9, 2013.
What Are the Main Threats to AbbVie's Humira?
Max Macaluso and Dave Williamson | Sep 9, 2013
A look at the AbbVie's second-quarter results and the pros and cons of selling the world's biggest blockbuster drug.
Johnson & Johnson's Earnings Made Easy
Max Macaluso and Dave Williamson | Aug 30, 2013
A run-down of this well-known health-care company's second-quarter results.
Catalysts Merck Investors Need to Watch
Max Macaluso and Dave Williamson | Aug 30, 2013
Which events do Merck investors need to pay close attention to?
Did This Big Pharma Giant Sink or Swim Last Quarter?
Max Macaluso and Dave Williamson | Aug 29, 2013
A look at Pfizer's top and bottom lines in the second quarter.
Market Checkup: Spotlight on Gilead
Max Macaluso and Dave Williamson | Aug 29, 2013
This edition of the Fool's health care show focuses on biotech company Gilead.
Market Checkup: Spotlight on AbbVie
Max Macaluso and Dave Williamson | Aug 29, 2013
A deep dive into AbbVie, a brand new company with a long history.
One More Big Pharma Bribery Scandal?
Max Macaluso and Dave Williamson | Aug 27, 2013
Another drugmaker faces claims of misconduct in China.
Why Rigel Investors Had a Dose of Disappointment Today
Max Macaluso and Dave Williamson | Aug 26, 2013
Shares of Rigel slid more than 13%. Where does this biotech stand today?
The Biotech Buyout Investors Have Been Waiting For
Max Macaluso and Dave Williamson | Aug 26, 2013
It's official: Amgen is acquiring Onyx Pharmaceuticals.
Market Checkup: A Biotech Buyout and Another Big Pharma Scandal Brewing in China?
Max Macaluso and Dave Williamson | Aug 26, 2013
The Motley Fool's health-care show "Market Checkup" for Aug. 26, 2013.
3 Reasons to Buy Bristol-Myers Squibb
Max Macaluso and Dave Williamson | Aug 22, 2013
Shares of this drugmaker have been on a steady rise since the start of 2013 -- are there any reasons left to buy?
Opportunities Bristol-Myers Squibb Investors Need to Watch
Max Macaluso and Dave Williamson | Aug 21, 2013
What are Bristol-Myers Squibb's biggest opportunities?
What's Behind Bristol-Myers Squibb's High Valuation?
Max Macaluso and Dave Williamson | Aug 21, 2013
Shares of Bristol-Myers Squibb have soared this year --- but what's been driving this growth?
Market Checkup: An In-Depth Look at Bristol-Myers Squibb
Max Macaluso and Dave Williamson | Aug 20, 2013
A close look at pharmaceutical company Bristol-Myers Squibb's last quarter, upcoming catalysts, and reasons to buy and sell the stock.
Market Checkup: Headlines for August 15, 2013
Max Macaluso and Dave Williamson | Aug 15, 2013
The Motley Fool's health-care show, "Market Checkup," for August 15, 2013.
Merck's Second Quarter: Highlights Investors Need to Know
Max Macaluso | Aug 14, 2013
Merck's total revenue dropped more than 10%, but it wasn't all bad for the drugmaker last quarter.
Time to Panic About Pfizer's Upcoming Patent Expirations?
Max Macaluso and Dave Williamson | Aug 13, 2013
Intellectual property is the lifeblood of the pharmaceutical industry -- how is Pfizer's patent portfolio holding up?